Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 12;15(1):e33685.
doi: 10.7759/cureus.33685. eCollection 2023 Jan.

The Efficiency and Safety of Mirabegron Monotherapy for the Treatment of Urge Incontinence in Women Aged >80 Years

Affiliations

The Efficiency and Safety of Mirabegron Monotherapy for the Treatment of Urge Incontinence in Women Aged >80 Years

Cihat Özcan et al. Cureus. .

Abstract

Objective We aimed to evaluate the efficacy and safety of mirabegron monotherapy in very older (>80 years) women with overactive bladder (OAB) who were discontinued anticholinergic drugs by the other departments. Material and methods The present retrospective study evaluated very older (>80 years) women with OAB who were discontinued anticholinergic drugs by the other departments between May 2018 and January 2021. Efficacy assessments were performed using Overactive Bladder-Validated Eight-Question (OAB-V8) scores before and after mirabegron monotherapy (12 weeks). Safety was evaluated based on adverse events (hypertension, nasopharyngitis, and urinary tract infection), electrocardiography, hypertension measure, uroflowmetry (UFM), and post-voiding. Patient data including demographic characteristics, diagnoses, values before and after mirabegron monotherapy, and adverse events were evaluated. Results A total of 42 very older (>80 years) women with OAB who used mirabegron monotherapy (50 mg per day) were included in this study. Frequency, nocturia, urgency, and total OAB-V8 scores were significantly lower after mirabegron monotherapy than before mirabegron monotherapy (p < 0.05, p < 0.05, p < 0.05, and p < 0.05, respectively). There was no significant difference between systolic-diastolic blood pressure and heart rate before and after mirabegron monotherapy treatment. Conclusion Mirabegron monotherapy is an effective and safe therapy in very older (>80 years) women with OAB.

Keywords: drug side effect; elderly population; mirabegron; urge incontinence; women.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Similar articles

References

    1. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Abrams P, Cardozo L, Fall M, et al. Am J Obstet Gynecol. 2002;187:116–126. - PubMed
    1. Management of urinary incontinence in women: scientific review. Holroyd-Leduc JM, Straus SE. JAMA. 2004;291:986–995. - PubMed
    1. Urinary incontinence and age at the first and last delivery: the Norwegian HUNT/EPINCONT study. Rortveit G, Hunskaar S. Am J Obstet Gynecol. 2006;195:433–438. - PubMed
    1. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. J Urol. 2015;193:1572–1580. - PubMed
    1. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Cui Y, Zong H, Yang C, Yan H, Zhang Y. Int Urol Nephrol. 2014;46:275–284. - PubMed

LinkOut - more resources